Bruker BioSciences 8-K 2012
Washington, DC 20549
Date of Report (Date of earliest event reported): July 10, 2012
(Exact name of registrant as specified in its charter)
40 Manning Road
Registrants telephone number, including area code: (978) 663-3660
Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the reporting obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On July 10, 2012, Dr. Dirk D. Laukien resigned from the Board of Directors (the Board) of Bruker Corporation (the Company) and from his position as Senior Scientific Fellow of the Company, effective immediately. Dr. Laukiens resignation was for personal reasons and there were no disagreements between Dr. Laukien and the Company regarding any matter relating to the Companys operations, policies or practices. The Company has not at this time appointed a replacement director to fill the vacancy created by Dr. Laukiens resignation.
Following Dr. Laukiens resignation, the Companys Board consists of eleven members, of whom seven are independent, and has two vacancies within the class of Class II directors currently serving terms expiring at the Companys 2014 Annual Meeting of Stockholders.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.